Recent advancement on albumin nanoparticles in treating lung carcinoma

Abstract

With the advancement of nanotechnology, many different forms of nanoparticles (NPs) are created, which specifically enhance anticancer drug delivery to tumour cells. Albumin bio-macromolecule is a flexible protein carrier for the delivery of drugs that is biodegradable, biocompatible, and non-toxic. As a result, it presents itself as an ideal material for developing nanoparticles for anticancer drug delivery. Toxicological investigations demonstrated that this novel drug delivery technique is safe for use in the human population. Furthermore, drug compatibility with the albumin nanoparticle is remarkable. The robust structure of the nanoparticle, high drug encapsulation, and customisable drug release make it a promising carrier option for the treatment of lung cancer. In this review, we summarise human serum albumin and bovine serum albumin in the targeted delivery of anticancer drugs to lung cancer cells.

Keywords:

• Lung cancer
• NSCLC
• nanoparticle
• bovine serum albumin (BSA)
• human serum albumin
• anticancer
• targeted drug delivery

Acknowledgments

The author (Waleed H. Almalki) extend their appreciation to the Deanship for Research & Innovation, Ministry of Education in Saudi Arabia for funding this research work through the project number: IFP22UQU4310387DSR157. The author (Prashant Kesharwani) acknowledges financial support from the Indian Council of Medical Research (ICMR), New Delhi, India, through Extramural Research Grants [35/10/2019-Nano/BMS and 5/13/8/2020/NCD-III].

Disclosure statement

There is no conflict of interest and disclosures associated with the manuscript.

Additional information

Funding

The author (Waleed H. Almalki) extend their appreciation to the Deanship for Research & Innovation, Ministry of Education in Saudi Arabia for funding this research work through the project number: IFP22UQU4310387DSR157. The author (Prashant Kesharwani) acknowledges financial support from the Indian Council of Medical Research (ICMR), New Delhi, India, through Extramural Research Grants [35/10/2019-Nano/BMS and 5/13/8/2020/NCD-III].